



Review article

Young-onset Parkinson's disease: Its unique features and their impact on quality of life

Raja Mehanna^{a,*}, Joseph Jankovic^b^a UT MOVE, Department of Neurology, University of Texas Health Science at Houston, Houston, TX, USA^b Parkinson's Disease Center and Movement Disorders Clinic, Department of Neurology, Baylor College of Medicine, Houston, TX, USA

ARTICLE INFO

Keywords:

Parkinson's disease
Young onset
Impact
Challenges
Management

ABSTRACT

Young-onset Parkinson's disease (YOPD), defined as age at onset between 21 and 40 years, presents unique motor and non-motor features that differentiate this subtype from the typical late onset Parkinson's disease (LOPD), starting after age 61. Because it affects patients in the prime of their life, it often has an extraordinary impact on their family, social, and professional life. While typically progressing at a slower rate than LOPD, patients with YOPD are more prone to develop levodopa-related motor complications, including dyskinesia. In this article we will review the clinical features and epidemiology of YOPD with focus on its impact on pregnancy, employment and family, as well as its particular diagnostic and management challenges.

1. Introduction

Parkinson's disease (PD) is a neurodegenerative disorder characterized by bradykinesia associated with either one or both of rest tremor and rigidity, as well as a variety of non-motor symptoms [1–4]. Young onset PD (YOPD), also referred to as early-onset PD, has been somewhat arbitrarily defined as PD with onset of motor symptoms between ages 21–40 years [5], while onset at or before age 20 defines juvenile PD and onset after 60 defines late-onset PD (LOPD) [6,7]. However, consensus is lacking and the reported maximal age for YOPD has varied from 40 to 55 [6,8–10], while minimal age for late onset PD (LOPD) has varied from 50 to 70 [6,11,12]. In this review, we specified the age ranges whenever possible when referring to specific studies.

Because it affects people in the prime of their productivity, YOPD carries its own set of clinical, social, and occupational challenges. While increased genetic predisposition, slower progression, and increased risk of levodopa related complications are well recognized in YOPD compared to LOPD [8,13–21], in this review we will focus on more pragmatic aspects of YOPD, namely its impact on the patients' personal, professional and family life, and various management challenges.

1.1. Method: search strategies and selection criteria

A systematic review of available literature in Pubmed with the following search terms was performed: Young OR early AND Parkinson AND each of diagnosis, impact, management, challenge, pregnancy,

employment, prevalence and family. All abstracts were reviewed for relevance to the topic of this review. Of the 1299 abstracts reviewed, 1066 were not considered relevant to the topic of this review as the search terms were vague to capture the most abstracts possible and minimize the risk of missing a relevant study; 133 abstracts were retained and the corresponding full articles were carefully reviewed. Of these, 71 full articles were considered relevant to the topic of this review and were included. Pubmed links and references from these articles were also scrutinized to identify other relevant studies as suggested by the references' titles. Similarly to the initial search, abstracts of potentially relevant references were reviewed, and, if considered relevant to the topic of this review, the corresponding full articles were reviewed. A total of 266 articles were reviewed.

1.2. Prevalence

The prevalence of PD in the western hemisphere has been reported to range from 130 to 200 per 100,000 in community based studies [22–25]. However, the prevalence and global burden related to PD is increasing at an exponential rate, largely due to rapidly aging population and improvement of life expectancy with a prevalence reported as high as 2000/100,000 in individuals over 80 years of age [22–25]. A review of 20 epidemiological studies from Asia reported a standardized all-age prevalence from 51 to 177 per 100,000 [26]. YOPD represents 5–7% of PD patients in the western hemisphere, but 10–14% in Japan [27]. It is unclear why YOPD would be relatively more frequent in

* Corresponding author. UT MOVE, Department of Neurology, University of Texas Health Science at Houston, 6410 Fannin Street, Suite 1010, Houston, Texas, USA.
E-mail address: raja.mehanna@uth.tmc.edu (R. Mehanna).

Japan, but the reported data is based on retrospective chart reviews and must be, therefore, interpreted cautiously [27].

1.3. Impact of YOPD

Young adults are more likely to be employed and have younger children and, therefore, the impact on overall productivity and prognosis is greater for YOPD than LOPD [28]. Because YOPD patients also have longer disease duration by the time they reach the age of the LOPD patients [29], they may suffer from more physical, economic, and psychological consequences. A number of cross-sectional studies have assessed the relationship between age at onset (AAO) of PD and quality of life (QOL) [6,30–34], the majority reporting an important association between younger onset and poor QOL [6,30–34]. This is likely due to a variety of factors including marital conflicts, difficulties with family life, social isolation and loss of occupation [28,34]. Greater worsening of QOL compared to the general population was seen in younger patients in one cross sectional study, attributed chiefly to physical limitations and role expectation [35].

Non-motor features of PD seem to have a particularly distressing impact on QOL of patients with YOPD. A cross sectional study of 426 PD patients and 402 controls reported that YOPD (AAO < 45) had a poorer QOL than LOPD (AAO > 45) and age matched controls, probably mediated to a large degree by a more depressive mood (OR 2.99 between YOPD and LOPD, $p < 0.01$, after adjustment for confounding factors) [33]. It is likely that social and psychosocial factors, including role expectations, contribute to greater impairment of QOL in young patients [34]. On the other hand, younger patients usually have a greater resilience because of stronger social support with younger and healthier spouse/care partner than older patients. Regarding longevity, a large retrospective US study found that the survival for PD patients was 32 years in YOPD (AAO ≤ 49), 18.5 years in middle onset PD (MOPD) (AAO = 50–69), and 9.3 years in LOPD (AAO ≥ 70) [10]. In comparison, median survival in US males for similar age groups and around the same period was 47 years, 22 years and 9.5 years respectively with estimated loss of years of life of 15 in YOPD, 3.5 years in MOPD and less than a year in LOPD [10]. This and other studies confirm prior reports of a longer survival but greater loss of years of productive life with a younger AAO [36–38].

1.4. Genetics

It has been well recognized that the younger the AAO, the higher the risk of genetic predisposition [39]. Indeed, a family history of PD is reported in 20% of YOPD patients vs 6.9% of LOPD patients, and the age-specific risk of PD is 7.8-fold higher in the relatives of patients with YOPD compared to 2.9-fold among the relatives of patients with LOPD [10,15]. It is beyond the scope of this article to comprehensively review the genetics of PD, but we wish to highlight the most frequent causes of monogenetic forms of YOPD and their main clinical differences compared to apparent sporadic YOPD (Table 1).

PARK 1 (SNCA, 4q21-q23), appears to have a more rapid progression with early motor fluctuations compared to sporadic PD [40]. Furthermore, it is manifested by more severe psychiatric features, especially when caused by gene duplication [41–43]. On the other hand, PARK2 (PRKN, 6q26) has a slow rate of progression, but is frequently associated with some atypical features such as prominent involvement of legs, freezing of gait, dystonia, dysautonomia, sleep benefit, and marked levodopa sensitivity associated with motor fluctuations and dyskinesia [44]. While these patients have less cognitive impairment [45], impulse control disorders may be more severe [46]. PARK6 (PINK1, 1p36) also has a relatively slow rate of progression and the clinical features overlap with PARK2 [47,48]. PARK7 (DJ-1, 1p36) is also similar to PARK2 but may be more frequently associated with blepharospasm [49]. PARK 9 (ATPA13A2, 1p36), also known as Kufor-Rakeb syndrome, is frequently associated with spasticity, dementia,

Table 1
Differential diagnosis of YOPD.

Genetic forms
PARK-SNCA (PARK1, 4q21-23)
PARK- <i>Parkin</i> (PARK2, 6q25.2–27)
PARK-PINK1 (PARK6, 1p36)
PARK-DJ-1 (PARK7, 1p36).
PARK-LRRK2 (PARK8, 12q12),
PARK-ATP13A2 (PARK9, 1p36)- Kufor-Rakeb syndrome
PARK-PLA2G6 (PARK14, 22q13.1)- PLAN
PARK-FBXO7 (PARK15, 22q12-q13)- early onset parkinsonian-pyramidal disease
PARK-VPS35 (PARK17, 12q11.2)
PARK- DNAJC6 (PARK19, 1p31.3)
PARK-SYNJ1 (PARK20, 21q22.11)
PARK-VPS13C (PARK23, 15q22.2)
DYT3 (TAF1, Xq13.1)- Lubag disease
DYT 5 (GCHI; 14q22.1-q22.2)- dopamine responsive dystonia
DYT 12 (ATP1A3, 19q13.2)- Rapid-onset dystonia parkinsonism
DYT16 (PRKRA, 2q31.2)- Young-onset dystonia parkinsonism
GBA,1q21- Gaucher's disease
Spinocerebellar ataxia 2 (ATXN2, 12q24)
Spinocerebellar ataxia 3 (ATXN3, 14q32.12)
22q11.2 deletion syndrome
Chediak-Higashi syndrome (LYST, 1q42.3)
Autosomal recessive hereditary spastic paraplegia (SPG-11; 15q21.1) and (SPG7,16q24.3)
Chorea-acanthocytosis (VPS13A, 9q21.2)
NBIA - PKAN (PANK2, 20p13)
MPAN (C19orf12, 19q12)- neurodegeneration with brain iron accumulation 4
BPAN (WDR45, Xp11.23)- beta-propeller protein-associated neurodegeneration
Huntington disease (Westphal variant) (HTT, 4p16.3)
Niemann-Pick type C (NPC1, 18q11.2 or NPC2, 14q24.3)
Frontotemporal dementia and parkinsonism linked to chromosome 17 (MAPT, 17q21.31)
Cerebrotendinous xanthomatosis (CYP27A1, 2q35)
Dentatorubral pallidolulysian atrophy (ATN1, 12p13.31)
Juvenile neuronal ceroid lipofuscinosis (multiple genes and disorders)
Neuronal intranuclear (hyaline) inclusion body disease (NIID)
Mitochondrial diseases
Paraneoplastic
Anti-Ma2-paraneoplastic limbic encephalitis
Anti-N-methyl-D-aspartate receptor (<i>anti-NMDAR</i>) encephalitis
Central nervous system infections
Encephalitis lethargica
Japanese encephalitis
HIV/AIDS encephalitis
Mycoplasma
Neurosyphilis,
Prion diseases
Progressive multifocal leukoencephalopathy
Toxoplasmosis
Subacute sclerosing panencephalitis
Non-infectious potentially treatable
Wilson's disease
Drug-induced parkinsonism
Dopa-responsive dystonia
Structural lesion (vascular, tumoral, demyelinating)
Hydrocephalus
Hypoparathyroidism
Pseudohypoparathyroidism,
Chronic liver failure
Extrapontine myelinolysis
Systemic lupus erythematosus
Others
Carbon monoxide, cyanide, and methanol poisoning

Legend: YOPD: young onset Parkinson's disease, NBIA: Neurodegeneration with brain iron accumulation, HSP: hereditary spastic paraplegia, PKAN: Pantothenate kinase-associated neurodegeneration (formerly called Hallervorden-Spatz syndrome), NBIA: neurodegeneration with brain iron accumulation

ophthalmoparesis as well as pallidal atrophy on brain imaging [50]. While homozygous GBA (1q21) mutations are known to cause Gaucher disease, heterozygous and occasional homozygous mutations in this gene have been found to markedly increase risk for PD, particularly in the Ashkenazi Jewish population [51,52]. These patients tend to have a

more rapid progression [53] and more severe cognitive impairment [54–58]. There is some heterogeneity between the different PD causing mutations on this gene, with severe mutations (including homozygotes or compound heterozygotes) having, compared to mild mutations, a higher PD risk (15 fold vs 3–4 fold) as well as earlier onset [59] and more severe motor and non-motor features [60].

1.5. Pregnancy

While there is no formal study on the impact of pregnancy on PD, a review of the literature reported worsening of PD-related symptoms in 31 out of 64 (48%) of pregnancies and improvement or status quo in 52% [61]. Of the pregnant women taking medications (83% of the total reported pregnancies), 36% worsened during pregnancy, compared to 67% of the untreated patients. This suggests that dopaminergic medications improve PD symptom during pregnancy and should be considered if the motor symptoms are troublesome. Among those who worsened (and for whom details of the PD therapeutic regimen was available), only 3 out of 9 pregnancies worsened because of a decrease in medication regimen motivated by the fear of teratogenicity and are detailed here. One patient was on rasagiline and pramipexole, both stopped [62], the second was on levodopa/carbidopa, entacapone, selegiline, and ropinirole, all of which were discontinued except for carbidopa/levodopa [63], while the third was on pramipexole which was stopped [64]. Parkinsonism worsened in 5 other pregnancies despite a stable or increased medication regimen, usually in the 2nd and 3rd trimester of pregnancy [65–69] while it worsened 1 month postpartum in 1 pregnancy despite an increase in medication doses during pregnancy [70]. No details were available regarding changes in the PD therapeutic regimen in the other 22 pregnancies [71,72]. A more recent series reported worsening in five of 14 pregnancies in PD patients. Parkinsonism worsened in one despite higher doses of levodopa, while the four others experienced transient worsening upon dose reduction that improved after subsequent dose increase: the first patient was only on pramipexole which was decreased during pregnancy, the second was on pramipexole which was decreased and rasagiline which was stopped, the third one was on benserazide/levodopa which was left unchanged and on amantadine and ropinirole both of which were discontinued, and the last patient was on a combination of pramipexole and rasagiline both of which were discontinued [73]. Overall, this suggests that worsening of parkinsonism is more likely a direct effect of the latter part of pregnancy, but can be exacerbated by medication reduction or withdrawal. The data is insufficient to suggest which agent's discontinuation is more likely to cause worsening. A common strategy seems to have been to continue levodopa if already used and discontinue other medications. Potential teratogenic effects of each agent should be taken into consideration as discussed below. In addition, pregnancy alters a woman's plasma volume, volume of distribution and metabolic state, leading to an alteration in drugs pharmacokinetics and a subsequent sub-therapeutic dosing of anti-parkinsonian medications. Thus, *anti*-PD medications must be frequently assessed during pregnancy and their dosage may need to be increased to prevent worsening of PD symptoms [74].

Many animal and human observations suggest that estrogen, particularly estradiol, has a protective as well as a dopaminergic effect in PD [18,61,75–84], while a smaller number suggests no benefit [75,85–87]. Other data suggest an increased risk of PD after exposure to exogenous estrogens [88,89]. During pregnancy, estrogen levels, particularly estradiol, increase. Estradiol has less affinity for estrogen receptors than estradiol [84,90] and, therefore, it probably plays a lesser role in modifying PD symptoms than the other hormones. Because of these inconsistent results, the role of estrogen and other female hormones in PD remains unclear. Some authors, however, observed that worsening of parkinsonism in the latter part of pregnancy in untreated PD patients could be secondary to a decrease in estrogens level at that period [63,67], and there have been anecdotal reports of worsening of PD

symptoms just before and during menses [91].

Regarding the impact of PD on pregnancy, it does not seem that the disease impacts fertility, conception or the birth process in women with PD [75]. A literature review of 75 babies born to women with idiopathic PD reported only three fetal malformations (osteomalacia, ventral septal defect and inguinal hernia) [61]. However, all of these occurred in babies born to women who were taking anti-parkinsonian medications (namely carbidopa/levodopa, entacapone, selegiline, and benserazide/levodopa). After reviewing the anti-parkinsonian agents reported in each case and the outcome of pregnancy, the authors concluded that carbidopa/levodopa was the safest agent to use in pregnant women with PD, with no evidence of increased rate of teratogenicity, birth complications or miscarriages. Dopamine agonists were deemed possibly safe without evidence of any teratogenicity, though not recommended because of concern over 3 (8.6%) miscarriages and 1 (3%) placental abruption. Amantadine, however, showed teratogenicity and increased risk of miscarriages in many reports as well as animal studies and, should not be used during pregnancy [61,71,72,92]. There was insufficient data to make any recommendations regarding the safety of MAO inhibitors or COMT inhibitors during pregnancy [61]. In an additional series reporting on 14 pregnancies, dopamine agonists were used in 13 patients, levodopa/benserazide in 4, levodopa/carbidopa/entacapone in 1, rasagiline in 7, amantadine in 4, and biperiden in 1 patient, with a combination therapy used in 9 patients. Among these, 1 elderly mother gave birth to a child with Down syndrome, and one sibling from a twin pregnancy exposed to pramipexole and rasagiline died from unexplained liver failure. One woman had a miscarriage while on pramipexole, and there was neonatal distress when taking levodopa/benserazide, piribedil, and rasagiline which resolved spontaneously. No clear association between the medications and the outcomes could be established [73].

Dopamine inhibits the release of prolactin and, as such, levodopa and dopamine agonists reduce or inhibit lactation, although women have been reported to successfully breastfeed while on bromocriptine and carbidopa/levodopa [90,93,94]. However, data regarding the amount of medication excreted in breast milk and its impact on the infant are very limited, and breastfeeding while taking any anti-parkinsonian medications is not generally recommended [61,68].

1.6. Employment

Employment is another important issue for patients with YOPD and their families, not only because of financial implications due to disability-related loss of income and early retirement, but also because of the effect on social interaction and self-esteem. Indeed, a study comparing 75 YOPD (AAO < 50) and 66 LOPD patients (AAO ≥ 50) reported that, among those who retired, 97% of the YOPD retired early vs 73% of those with LOPD ($p = 0.003$) [34]. Other studies have found that 54% of YOPD patients retire early and 94% are likely to give up work within 10 years of disease onset [31].

Problems related to employment and long-term disability might be population specific. One retrospective cohort review of 88 Irish patients with PD onset before age 65 years reported that unemployment rates for males were 1.6 times higher compared to the general population, but unemployment among women was not significantly affected by PD [32]. Specifically, males aged 55–64 years were twice more likely to be unemployed than the general population. Median retirement age was 4 years earlier in PD patients compared to the general population. The authors also found that the median time to loss of employment was 7 years, with 40% still employed after 5 years from onset, and 14% after 10 years. Early age at PD onset and early diagnosis were associated with prolonged employment, consistent with the notion of slower progression of the disease in patients with earlier onset. These findings are consistent with other studies [8,95–97]. However, time from PD symptom onset to loss of employment was not influenced by gender, education status, type of work (manual, office, etc.), hours of work (full

time or part time), physical demands, use of hands or mental demands of the job. Among those who were still working at the time of the study, 77% had made adjustments at work, while 67% of those who had become unemployed or who had retired as a result of PD believed that adjustments such as changes in work schedule, type of work or having a longer time to complete tasks could have helped them to stay employed longer [32].

The challenge of staying employed with YOPD is not just related to the motor symptoms of PD. While physical disability is frequently cited as the greatest source of difficulty at work, many patients are most bothered by the perception that others might have of their impairment rather than by their impairment itself [32]. This higher level of stigma in YOPD patients [28] can manifest as a reluctance to seek help and ask for adjustments at work, which in turn decreases the chances of staying employed. While there are no formal studies assessing it, employers need to be educated about the work changes that could be beneficial to their employees with YOPD, such as the use of occupational therapy devices, reassignment to a desk job, or more lenient deadlines [32,66,97]. The importance of appropriate support in the workplace has already been well established [32,66,97] but does not seem to be sufficiently implemented. This requires employee's and employer's awareness and education about the patient's right to have reasonable adjustments made and what resources are available to do so. Finally, depression and addictive behaviors, more frequent in YOPD patients as we will detail below, likely contribute as well to employment related challenges [98].

Loss of earnings related to YOPD has been estimated to account for 65% of the total cost of the disease [32]; even those PD patients who continue to work earn markedly reduced incomes [99]. The burden of unemployment from YOPD goes beyond a financial cost, including social isolation, feelings of futility, lack of purpose, and lack of daily structure. In the study by Murphy et al. [32], 82% of those who had stopped working as a result of PD were dissatisfied with their unemployment status.

Patients with YOPD are particularly likely to face financial challenges and economic strain because of decreased working capacity, loss of income due to decreased productivity at work and early retirement, and inability to advance in the workplace, as well as the cost of medications and treatment [100]. Many people with YOPD seek long-term disability because part time employment may not provide enough income. Unemployed YOPD patients without family support face a grim future as they can become marginalized members of society and forced into low cost housing or early nursing home placement [101].

In summary, YOPD patients carry a greater socioeconomic burden when compared with their older-onset counterparts [28,34,102] because of the adverse impact of the disease on their financial status which often contributes to marital conflicts, social isolation, mood disorder, sexual dysfunction, and other aspects of family life [23,28,34].

1.7. Family

While no formal, controlled study has assessed the impact of YOPD on the patient's marriage and family, different authors suggest that YOPD presents an additional challenge, as many YOPD patients are only recently married and may have young children. PD can also affect sexual life, with a particularly stronger impact in younger patients [103]. Depression can decrease libido which leads to sexual difficulties and can, in turn, contribute to or exacerbate underlying depression. In addition, bradykinesia and rigidity can interfere with movements while sexual arousal can worsen levodopa induced dyskinesia [103]. When present, drooling can also decrease attractiveness. Erection can also be difficult to reach and/or maintain, and ejaculation can be either premature or delayed, the latter usually secondary to prescribed anti-depressants [103]. Marriages or relationships of shorter duration can be more vulnerable to the strain a chronic illness can impose than those of longer duration

[104]. However, younger patients usually have younger and healthier spouse/partners who can provide more support. On the other hand, YOPD patients who have young children may be concerned and have a sense of guilt for not being able to fully devote themselves to them. Finally, the higher risk of burn out in caregiver of PD patients with ICD, depression and anxiety [105] and the higher frequency of these non-motor symptoms in YOPD (see below) raises the concern for a higher risk of burnout among YOPD caregiver, although this has not been formally demonstrated [105].

2. Clinical aspects

2.1. Diagnostic challenges

Although the clinical picture of YOPD usually resembles that of older-onset PD [8,29], the differential diagnosis is different [Table 1]. In a chart review of 337 patients, Rana et al. [9] found that YOPD (AAO < 45) patients had a much longer latency from onset to diagnosis (25 months vs 9 months, $p < 0.001$), and required more neurologist visits (3.64 vs 1.57, $p = 0.002$) and investigations (4.86 vs 0.36, $p < 0.001$) to receive the diagnosis. This observation underlines the challenge of making a diagnosis of PD in young individuals, despite a clinical presentation very similar to LOPD as neurologists suspecting PD seem to give preference to diagnoses other than PD in patients with symptoms presenting at young onset [9]. Indeed YOPD more likely than LOPD received a functional (psychogenic) diagnosis [106].

Another challenge could be a decreased acceptance of the diagnosis by younger patients. This can delay initiation of the appropriate therapy and further increased the negative impact of the disease on all aspects of the patient's life. Psychological counseling and support of the patient and the family should be provided in these circumstances.

2.2. Motor features

In a large retrospective study assessing the impact of AAO on clinical features and evolution of 593 patients, rigidity and painful cramps as the predominant initial symptoms were more frequent in YOPD (AAO ≤ 49) patients while gait instability as the predominant initial symptom was more frequent in older-onset patients [10]. While there was no statistically significant difference in the frequency of tremor or bradykinesia as the predominant initial symptom among the groups, tremor was the most frequent initial symptom in all groups with an overall frequency close to 62%, and the frequency increased with advancing AAO. These observations confirmed results of previous studies [107], while contrasting with others whose results indicated both an increased or decreased rate of tremor in younger onset patients [108–111]. Another review of 422 patients also reported that rigidity was a more frequent presenting symptom in the younger group (AAO < 50) [112]. In a study of 358 community-based and regional patients with PD, dystonia as a presenting symptom was reported in 20% of YOPD (AAO < 45) but only 3% of LOPD (AAO > 64). Within 2 years of onset, dystonia developed in an additional 11% of YOPD and 1% of LOPD, suggesting that dystonia might be more frequent in YOPD [107]. Most studies agree that the YOPD patients tend to have a slower progression of motor symptoms than those with LOPD [7,38,113–116].

These clinical differences between YOPD and LOPD might have an anatomic substrate. In one study, Liu et al. [117] compared the striatal patterns of dopaminergic degeneration between YOPD (AAO ≤ 50) and LOPD (AAO > 50), as examined with [11C]-CFT PET. YOPD patient's DAT scans showed more sparing of the caudate compared with the putamen, while DAT scans from patients with LOPD showed relatively uniform involvement of both caudate and putamen. Since the caudate is more involved in psychomotor and complex cognitive functions [118–120], this might provide an explanation for the lower prevalence of these non-motor symptoms in YOPD compared to LOPD. On the other hand, a positron emission tomography (PET) and 18F-fluorodopa scans

study which included 27 patients reported a higher PD-induced increase in dopamine turnover compared with the decrease in dopamine synthesis and storage rate in patients of younger age compared with older patients. The authors suggested this implied greater alteration of dopamine turn over in YOPD that could lead to larger swings in synaptic dopamine levels, which has been suggested as a possible contributor to a greater risk of motor fluctuations [121]. In addition, a longitudinal PET assessment study reported a greater loss of putaminal dihydrotetabenazine (DTBZ), reflecting a greater decrease in the density of the vesicular monoamine transporter type 2, in YOPD (average age 35) compared to LOPD (average age 70), with a slower progression and longer pre-symptomatic phase in the YOPD group. The authors concluded that YOPD patients progress more slowly and endure more damage to the dopaminergic system before motor symptoms develop, suggesting more efficient compensatory mechanism [122]. The higher risk of dyskinesia in YOPD patients could then also be attributed to a greater extent of neuronal loss in patients with similar severity of motor symptoms than their LOPD counterpart.

YOPD patients have less comorbidities, slower disease progression [38,113,123–125], less frequent gait disturbances as well as delayed falls and freezing [8,12], and delayed cognitive decline [29] compared to those with LOPD, and the lower frequency of non-dopamine responsive axial symptoms (dysphagia and postural instability) may be more dependent on AAO rather than disease duration even 20 years after onset [126]. On the other hand, some of the differences, e.g. cognitive decline, may be more dependent on absolute age rather than disease duration [29].

2.3. Response to dopaminergic therapies

Several studies have shown that YOPD is an independent risk factor for the development of levodopa-related motor fluctuations and dyskinesia [10,125,127] with a shorter latency from treatment onset in patients with YOPD compared to those with LOPD [5,8,128,129]. In two population based studies, the prevalence of dyskinesia was reported to decrease with advancing AAO; the 5-year risk was 50% with AAO before 50, 26% with AAO between 60 and 69, and 16% with AAO after 70 [130]. The authors suggested that the risk of dyskinesia was reduced by 20%–30% for each 10 years of older AAO [131]. To our knowledge, no data has been published reporting a difference in the nature or the severity of LID between YOPD and LOPD. While the use of levodopa is frequently reported as a risk factor for the development of motor fluctuations the notion of delaying levodopa therapy has been challenged [132,133]. In a cross-sectional case-control analysis of 91 patients in Ghana followed for at least 6 months after the initiation of levodopa therapy compared with 2282 Italian patients recruited during the same period, disease duration at the occurrence of motor fluctuations and dyskinesia was similar in the two populations even though levodopa therapy was introduced later in Ghana (mean disease duration 4.2 ± 2.8 vs 2.4 ± 2.1 years, $p < 0.001$) [134]. This suggests that delaying onset of levodopa therapy does not necessarily prevent levodopa-related complications [135]. Despite this evidence, a common practice is to avoid the use of levodopa as long as possible, especially in YOPD, and to consider alternatives such as dopamine agonists [8,136–139]. This “levodopa phobia”, however, often leads to inappropriately delayed effective treatment in individuals who need it the most, the otherwise productive patients with YOPD, with greater cumulative disability [135,140]. Furthermore, dopamine agonists can be associated with sudden sleep attacks [141], and other side effects, such as edema and impulse control disorder, which present an additional challenge to young patients who work, are looking after young children, or drive. YOPD patients are particularly prone to develop compulsive behaviors associated with dopamine agonists, such as hypersexuality, compulsive shopping and gambling and other features of impulse control disorder [142–144].

Therefore, the time and choice of *anti*-PD therapy must be

individualized and tailored to the needs of the patient rather than AAO [145]. As such, levodopa should be started as soon as needed to reduce motor disability and its impact on professional and family life, with fewer potentially serious side effects than dopamine agonists. Once motor complications develop, their management is very similar in YOPD and LOPD, a discussion beyond the scope topic of this review [146–156].

Finally, a small European monocentric observational study ($n = 54$, average age 62 years) reported a lower drug compliance among younger patients, possibly related to a higher rate of depression [157], while a larger US population based study ($n = 7593$, 94% aged > 65 years) reported a decreased adherence with older age, possibly related to decreased income [158]. However, these findings were based on age at assessment rather than age at onset, and there is no data demonstrating any impact of AAO on medication compliance in PD.

2.4. Non motor features

YOPD patients are more likely than LOPD to face occupational and lifestyle challenges, not only because of motor impairment associated with their disease as noted above [8,28,159,160], but also because of emergence of relatively unique non-motor comorbidities, such as depression [159], loss of libido, sexual dysfunction, future uncertainty [163], and other problems [103]. In one study, depression occurred twice as frequently in patient with YOPD (AAO ≤ 49) as in patients with LOPD (AAO ≥ 70 years) [10]. Although YOPD patients have a lower risk for dementia [164], several studies found that YOPD patients had a higher rate of depression and restless legs syndrome [8,12,34,102,125,126,165,166] as well as sexual dysfunction [167] than their older counterparts (Tables 2–4).

PD patients may be at higher risk for addictive behaviors [168], possibly because of the disease itself, but also as a side effect of dopaminergic medications used to treat the motor symptoms of PD. Impulse control disorders, such as gambling, compulsive shopping, and sexual addiction were reported with a nearly three-fold increase in those taking dopamine agonists (often a preferred class of *anti*-PD drugs in YOPD) and a 50% increase associated with levodopa treatment [169]. Dopamine dysregulation syndrome has been also associated with young AAO, especially in males [170].

In a cross sectional study of disabled Americans aged 30–54 years who were receiving Medicare, 57.7% of YOPD (AAO < 49) disabled cases were evaluated or treated for a psychiatric illness of any kind, and 40.7% of YOPD patients received care for depression in either the outpatient or inpatient setting, almost the double the frequency observed in the non-YOPD Medicare 30–54 year old beneficiaries for that year [171]. In addition, a diagnosis of, or treatment for, substance abuse or dependence was noted in 17% of YOPD patients, corresponding to a three-fold increase in the likelihood of these illnesses

Table 2

Findings that are less frequent, less severe or delayed in YOPD compared to LOPD [180–188].

Disease progression
Gait disturbances, including freezing of gait
Falls
Dementia
Anxiety
Psychosis
Double vision
Gastrointestinal complaints (constipation, gastroparesis)
Urinary complaints
Impairment of taste and smell
Daytime sleepiness
REM sleep behavior disorders
Insomnia
Nightmares

Legend: YOPD: young onset Parkinson's disease; LOPD: late onset Parkinson's disease.

Table 3

Findings that are more frequent or more severe in YOPD compared to LOPD.

Social stigma
Motor fluctuations
Levodopa-induced dyskinesia
Dopaminergic-induced impulse control disorder
Depression
Restless legs syndrome
Decreased quality of life
Loss in years of life
Familial/social difficulties
Sexual dysfunction

Legend: YOPD: young onset Parkinson's disease; LOPD: late onset Parkinson's disease.

Table 4

Findings that are more frequent or more severe in YOPD compared to age matched population.

Depression
Dysthymia
Generalized anxiety
Panic disorder
Social anxiety disorder
Acute adjustment disorder/psychosocial dysfunction
Impulsive compulsive disorders (gambling, shopping, and sexual addiction)*
Psychosis*
Substance abuse/dependence*
Dementia/mild cognitive impairment
Decreased life expectancy
Decreased quality of life
Early retirement/disability
Familial/social difficulties
Difficulty driving
Excessive daytime sleepiness

(* = from PD or treatment).

Legend: YOPD: young onset Parkinson's disease.

compared to the general disabled population. In that same cohort, substance abuse/dependence was the most frequently documented reason for hospitalization in YOPD, accounting for 82.6% of psychiatric hospitalizations, and 11.6% of all YOPD patient hospitalizations that year. YOPD patients also had a higher frequency of hospital admissions compared to non-YOPD disabled patients for impulse control disorders (fivefold increase), psychosis (threefold increase), acute adjustment disorder/psychosocial dysfunction (fourfold increase), and alcohol/substance abuse (twofold increase), without clear correlation to age, sex or race. Admissions for depressive and non-depressive psychiatric disorders were 1.4 fold more frequent in the YOPD disabled population [171]. That same cohort reported mild cognitive impairment and dementia in 19% of YOPD disabled patients, a 7-fold increase compared to same age non-YOPD disabled patients, with a steady increase in frequency with age. It is important to note that the denominator of these frequencies was the number of disabled, not total, YOPD patients. As such, the prevalence of cognitive decline, dementia, psychiatric illness, addiction and hospital admissions might be higher than in a working population of YOPD patients.

Additionally, because of difficulty with multi-tasking and processing, driving is frequently impaired in PD [172] and must be stopped at some point during the evolution of the disease. This can have particular implications for YOPD patients not only in terms of loss of independence, but also in relating to employment and self-esteem [6].

Finally, YOPD patients with poorly developed coping skills are at risk of exhibiting anger and self-destructive patterns of behavior [102]. They also seem to be more vulnerable to the lure of “miracle cures”, “media hype”, and unproven therapies such as supplements and stem cells [173]. The education of YOPD patients about their disease and providing adequate coping strategies and support system can become a challenge requiring a multidisciplinary team approach, consisting of

social workers, physical and rehabilitation therapists and other allied health professionals [102,174–178]. In the specific case of YOPD patients, these health professionals can promote confidence and self-esteem, especially as related to their parenting and employment status [102]. Some patients with advanced YOPD may require counseling about accessing human resources and applying for disability despite their young age. Some authors advise that teenagers and young children be informed in a candid, but sensitive, manner about their parent's illness, be encouraged to take a responsible part in maintaining the family unity, and be part of decision making affecting the family [102]. These children may need professional counseling if their parent's illness is having a negative effect on their schooling and relationships.

There is a remarkable paucity of data based on prospective long-term studies that follow YOPD patients longitudinally until advanced age. Although cognitive decline seems to be a function of age rather than duration of the disease [179] and YOPD evolves slower than LOPD, the disease can still become devastating later in life. While we have focused on the differences between YOPD and LOPD, it is important to acknowledge that there is a marked variability in the expression and progression of the disease and that the two subtypes often overlap and may relate to other PD-subtypes [7,113–116].

3. Conclusion

YOPD presents unique challenges compared to LOPD as it typically affects patients in the prime of their life, impacting social, occupational, and familial dynamics, coupled with higher frequency of levodopa-related motor complications. Recognizing and addressing these challenges requires involvement of not only the patient and the treating physicians, but also the patient's spouse and children, as well as mental health providers, social workers, physical and rehabilitation therapists, and other health care professionals, with the goal of keeping the patients active and engaged in their family and to remain as productive as possible for as long as possible. We suggest that the primary role of the treating neurologist is to direct and help coordinate the care to maintain the most optimal quality of life.

Funding sources

None.

Conflict of interest/disclosures

Dr Mehanna serves as a consultant for Global Kinetic Corporation, and is on the speaker bureau for TEVA, Adamas Pharmaceuticals and Acorda Therapeutics. He has received research grants from Lundbeck, Acorda and Solstice Neurosciences.

Dr. Jankovic has received research and/or training grants from: Adamas Pharmaceuticals, Inc; Biotie Therapies; Civitas/Acorda Therapeutics; Dystonia Coalition; F. Hoffmann-La Roche Ltd; Medtronic Neuromodulation; Michael J Fox Foundation for Parkinson Research; National Institutes of Health; Neurocrine Biosciences; NeuroDerm Ltd; Parkinson's Foundation; Nuvelution; Parkinson Study Group; Pfizer Inc; Prothena Biosciences Inc; Psyadon Pharmaceuticals, Inc; Revance Therapeutics, Inc; Sangamo BioSciences, Inc.; St. Jude Medical; Teva Pharmaceutical Industries Ltd.

Dr. Jankovic has served as a consultant or as an advisory committee member for: Adamas Pharmaceuticals, Inc; Allergan, Inc; Merz Pharmaceuticals; Pfizer Inc; Prothena Biosciences Inc; Revance Therapeutics, Inc; Teva Pharmaceutical Industries Ltd.

References

- [1] R. Mehanna, J. Jankovic, *Respiratory problems in neurologic movement disorders*, *Park. Relat. Disord.* 16 (2010) 628–638.
- [2] J.A. Obeso, M. Stamelou, C.G. Goetz, W. Poewe, A.E. Lang, D. Weintraub, D. Burn,

- G.M. Halliday, E. Bezdard, S. Przedborski, S. Lehericy, D.J. Brooks, J.C. Rothwell, M. Hallett, M.R. DeLong, C. Marras, C.M. Tanner, G.W. Ross, J.W. Langston, C. Klein, V. Bonifati, J. Jankovic, A.M. Lozano, G. Deuschl, H. Bergman, E. Tolosa, M. Rodriguez-Violante, S. Fahn, R.B. Postuma, D. Berg, K. Marek, D.G. S Standaert, D.J. Surmeier, C.W. Olanow, J.H. Kordower, P. Calabresi, A.E. Schapira, J. Stoessl, Past, present and future of Parkinson's disease: a special essay on the 200th anniversary of the shaking palsy, *Mov. Disord.* 32 (2017) 1264–1310.
- [3] D. Berg, C.H. Adler, B.R. Bloem, P. Chan, T. Gasser, C.G. Goetz, G. Halliday, A.E. Lang, S. Lewis, Y. Li, I. Liepelt-Scarfone, I. Litvan, K. Marek, C. Maetzler, T. Mi, J. Obeso, W. Oertel, C.W. Olanow, W. Poewe, S. Rios-Romenets, E. Schäffer, K. Seppi, B. Heim, E. Slow, M. Stern, I.O. Bledsoe, G. Deuschl, R.B. Postuma, Movement disorder society criteria for clinically established early Parkinson's disease, *Mov. Disord.* 33 (2018) 1643–1646.
- [4] R.B. Postuma, W. Poewe, I. Litvan, S. Lewis, A.E. Lang, G. Halliday, C.G. Goetz, P. Chan, E. Slow, K. Seppi, E. Schaffer, S. Rios-Romenets, T. Mi, C. Maetzler, Y. Li, B. Heim, I.O. Bledsoe, D. Berg, Validation of the MDS clinical diagnostic criteria for Parkinson's disease, *Mov. Disord.* 33 (2018) 1601–1608.
- [5] N. Quinn, P. Critchley, C.D. Marsden, Young onset Parkinson's disease, *Mov. Disord.* 2 (1987) 73–91.
- [6] A. Schrag, J.M. Schott, Epidemiological, clinical, and genetic characteristics of early-onset parkinsonism, *Lancet Neurol.* 5 (2006) 355–363.
- [7] M.A. Thengnatt, J. Jankovic, Parkinson disease subtypes, *JAMA Neurol.* 71 (2014) 499–504.
- [8] A. Schrag, M. Jahanshahi, N. Quinn, What contributes to quality of life in patients with Parkinson's disease? *J. Neurol. Neurosurg. Psychiatry* 69 (2000) 308–312.
- [9] A.Q. Rana, I. Siddiqui, M. Yousuf, Challenges in diagnosis of young onset Parkinson's disease, *J. Neurol. Sci.* 323 (2012) 113–116.
- [10] R. Mehanna, S. Moore, J.G. Hou, A.I. Sarwar, E.C. Lai, Comparing clinical features of young onset, middle onset and late onset Parkinson's disease, *Park. Relat. Disord.* 20 (2014) 530–534.
- [11] M.M. Wickremaratchi, D. Perera, C. O'Loghlen, D. Sastry, E. Morgan, A. Jones, P. Edwards, N.P. Robertson, C. Butler, H.R. Morris, Y. Ben-Shlomo, Prevalence and age of onset of Parkinson's disease in Cardiff: a community based cross sectional study and meta-analysis, *J. Neurol. Neurosurg. Psychiatry* 80 (2009) 805–807.
- [12] M.M. Wickremaratchi, Y. Ben-Shlomo, H.R. Morris, The effect of onset age on the clinical features of Parkinson's disease, *Eur. J. Neurol.* 164 (2009) 450–456.
- [13] J.E. Ahlskog, Parkin and PINK1 parkinsonism may represent nigral mitochondrial cytopathies distinct from Lewy body Parkinson's disease, *Park. Relat. Disord.* 15 (2009) 721–727.
- [14] E. Lohmann, M. Periquet, V. Bonifati, N.W. Wood, G. De Michele, A. M. Bonnet, V. Fraix, E. Broussolle, M.W. Horstink, M. Vidailhet, P. Verpillat, T. Gasser, D. Nicholl, H. Teive, S. Raskin, O. Rascol, A. Destée, M. Ruberg, F. Gasparini, G. Meco, Y. Agid, A. Durr, A. Brice A French Parkinson's Disease Genetics Study Group, European Consortium on Genetic Susceptibility in Parkinson's Disease, How much phenotypic variation can be attributed to parkin genotype? *Ann. Neurol.* 54 (2003) 176–185.
- [15] H. Payami, S. Zarepari, D. James, J. Nutt, Familial aggregation of Parkinson disease: a comparative study of early-onset and late-onset disease, *Arch. Neurol.* 59 (2002) 848–850.
- [16] C.M. Tanner, R. Ottman, S.M. Goldman, J. Ellenberg, P. Chan, R. Mayeux, J.W. Langston, Parkinson disease in twins: an etiologic study, *J. Am. Med. Assoc.* 281 (1999) 341–346.
- [17] C.M. Tanner, Y. Ben Shlomo, Epidemiology of Parkinson's disease, *Adv. Neurol.* 80 (1999) 153–159.
- [18] C.B. Lucking, A. Durr, V. Bonifati, J. Vaughan, G. De Michele, T. Gasser, B.S. Harhangi, G. Meco, P. Denefle, N.W. Wood, Y. Agid, A. Brice/French Parkinson's Disease Genetics Study Group, European consortium on genetic susceptibility in Parkinson's disease, association between early onset Parkinson's disease and mutations in the parkin gene: French Parkinson's disease genetics study group, *N. Engl. J. Med.* 342 (2000) 1560–1567.
- [19] S. Olgiati, M. Quadri, M. Fang, J.P. Rood, J.A. Saute, H.F. Chien, C.G. Bouwkamp, J. Graafland, M. Minneboo, G. J. Breedveld, J. Zhang, International Parkinsonism Genetics Network, F.W. Verheijen, A.J. Boon, A.J. Kievit, L.B. Jardim, W. Mandemakers, E.R. Barbosa, C.R. Rieder, K.L. Leenders, J. Wang, V. Bonifati, DNAJC6 mutations associated with early-onset Parkinson's disease, *Ann. Neurol.* 79 (2016) 244–256.
- [20] N.J. Butcher, T.R. Kiehl, L.N. Hazrati, E.W. Chow, E. Rogaeva, A.E. Lang, A.S. Bassett, Association between early-onset Parkinson disease and 22q11.2 deletion syndrome: identification of a novel genetic form of Parkinson disease and its clinical implications, *JAMA Neurol.* 70 (2013) 1359–1366.
- [21] D.J. Kamphuis, H. Koelman, A.J. Lees, M.A. Tijssen, Sporadic rapid onset dystonia-parkinsonism presenting as Parkinson's disease, *Mov. Disord.* 21 (2006) 118–119.
- [22] A. Schrag, Y. Ben-Shlomo, N. Quinn, Cross sectional prevalence survey of idiopathic Parkinson's disease and parkinsonism in London, *BMJ* 321 (2000) 21–22.
- [23] E.R. Dorsey, B.R. Bloem, The Parkinson pandemic—A call to action, *JAMA Neurol.* 75 (2018) 9–10.
- [24] T. Pringsheim, N. Jette, A. Frolkis, T.D. Steeves, The prevalence of Parkinson's disease: a systematic review and meta-analysis, *Mov. Disord.* 29 (2014) 1583–1590.
- [25] M. Wanneveich, F. Moisan, H. Jacqmin-Gadda, A. Elbaz, P. Joly, Projections of prevalence, lifetime risk, and life expectancy of Parkinson's disease (2010–2030) in France, *Mov. Disord.* 33 (2018) 1449–1455.
- [26] W. Muangpaisan, H. Hori, C. Brayne, Systematic review of the prevalence and incidence of Parkinson's disease in Asia, *J. Epidemiol.* 19 (2009) 281–293.
- [27] L. I Golbe, Young-onset Parkinson's disease: a clinical review, *Neurology* 41 (1991) 168–173.
- [28] S.M. Calne, A. Kumar, Young onset Parkinson's disease, Practical management of medical issues, *Park. Relat. Disord.* 14 (2008) 133–142.
- [29] A. Schrag, Y. Ben-Shlomo, R. Brown, C.D. Marsden, N. Quinn, Young-onset Parkinson's disease revisited—clinical features, natural history, and mortality, *Mov. Disord.* 13 (1998) 885–894.
- [30] A. Kupsch, W.H. Oertel, Selegiline, pregnancy, and Parkinson's disease, *Mov. Disord.* 13 (1998) 175–176.
- [31] A. Schrag, P. Banks, Time of loss of employment in Parkinson's disease, *Mov. Disord.* 21 (2006) 1839–1843.
- [32] R. Murphy, N. Tubridy, H. Kevelighan, S. O'Riordan/Parkinson's disease, How is employment affected? *Ir. J. Med. Sci.* 182 (2013) 415–419.
- [33] M.D. Knipe, M.M. Wickremaratchi, E. Wyatt-Haines, H.R. Morris, Y. Ben-Shlomo, Quality of life in young- compared with late-onset Parkinson's disease, *Mov. Disord.* 26 (2011) 2011–2018.
- [34] A. Schrag, A. Hovris, D. Morley, N. Quinn, M. Jahanshahi, Young versus older-onset Parkinson's disease: impact of disease and psychosocial consequences, *Mov. Disord.* 18 (2003) 1250–1256.
- [35] A. Schrag, M. Jahanshahi, N. Quinn, How does Parkinson's disease affect quality of life? A comparison with quality of life in the general population, *Mov. Disord.* 15 (2000) 1112–1118.
- [36] L.S. Ishihara, A. Cheesbrough, C. Brayne, A. Schrag, Estimated life expectancy of Parkinson's patients compared with the UK population, *J. Neurol. Neurosurg. Psychiatry* 78 (2007) 1304–1309.
- [37] E.B. Forsaa, J.P. Larsen, T. Wentzel-Larsen, G. Alves, What predicts mortality in Parkinson disease? a prospective population-based long-term study, *Neurology* 75 (2010) 1270–1276.
- [38] P.A. Kempster, S.S. O'Sullivan, J.L. Holton, T. Revesz, A.J. Lees, Relationships between age and late progression of Parkinson's disease: a clinico-pathological study, *Brain* 133 (2010) 1755–1762.
- [39] H. Deng, P. Wang, J. Jankovic, The genetics of Parkinson disease, *Ageing Res. Rev.* 42 (2018) 72–85.
- [40] M. Kasten, C. Klein, The many faces of alpha-synuclein mutations, *Mov. Disord.* 28 (2013) 697–701.
- [41] M.C. Chartier-Harlin, J. Kachergus, C. Roumier, V. Mouroux, X. Douay, S. Lincoln, C. Leveque, L. Larvor, J. Andrieux, M. Hulihan, N. Waucquier, L. Defebvre, P. Amouyel, M. Farrer, A. Destée, Alpha-synuclein locus duplication as a cause of familial Parkinson's disease, *Lancet* 354 (2004) 1167–1169.
- [42] K. Nishioka, O.A. Ross, K. Ishii, J.M. Kachergus, K. Ishiwata, M. Kitagawa, S. Kono, T. Obi, K. Mizoguchi, Y. Inoue, H. Imai, M. Takahashi, Y. Mizuno, M.J. Farrer, N. Hattori, Expanding the clinical phenotype of SNCA duplication carriers, *Mov. Disord.* 24 (2009) 1811–1819.
- [43] S. Petrucci, M. Ginevrino, E.M. Valente, Phenotypic spectrum of alpha-synuclein mutations: new insights from patients and cellular models, *Park. Relat. Disord.* 22 (Suppl1) (2016) S16–S20.
- [44] C.Y. Kim, R.N. Alcalay, Genetic forms of Parkinson's disease, *Semin. Neurol.* 37 (2017) 135–146.
- [45] R.N. Alcalay, E. Caccappolo, H. Mejia-Santana, M.X. Tang, L. Rosado, M. Orbe Reilly, D. Ruiz, E.D. Louis, C.L. Comella, M.A. Nance, S.B. Bressman, W.K. Scott, C.M. Tanner, S.F. Mickel, C.H. Waters, S. Fahn, L.J. Cote, S.J. Frucht, B. Ford, M. Rezak, K.E. Novak, J.H. Friedman, R.F. Pfeiffer, L. Marsh, B. Hiner, H. Payami, E. Molho, S.A. Factor, J.G. Nutt, C. Serrano, M. Arroyo, R. Ottman, M.W. Pauculo, W.C. Nichols, L.N. Clark, K.S. Marder, Cognitive and motor function in long-duration PARKIN-associated Parkinson disease, *JAMA Neurol.* 71 (2014) 62–67.
- [46] F. Morgante, A. Fasano, M. Ginevrino, S. Petrucci, L. Ricciardi, F. Bove, C. Criscuolo, M. Moccia, A. De Rosa, C. Sorbera, A.R. Bentivoglio, P. Barone, G. De Michele, M.T. Pellecchia, E.M. Valente, Impulsive-compulsive behaviors in parkin-associated Parkinson disease, *Neurology* 87 (2016) 1436–1441.
- [47] E.M. Valente, A.R. Bentivoglio, P.H. Dixon, A. Ferraris, T. Ialongo, M. Frontali, A. Albanese, N.W. Wood, Localization of a novel locus for autosomal recessive early-onset parkinsonism, PARK6, on human chromosome 1p35-p36, *Am. J. Hum. Genet.* 68 (2001) 895–900.
- [48] V. Bonifati V., C.F. Rohé, G.J. Breedveld, E. Fabrizio, M. De Mari, C. Tassorelli, A. Tavella, R. Marconi, D.J. Nicholl, H.F. Chien, E. Fincati, G. Abbruzzese, P. Marini, A. De Gaetano, M.W. Horstink, J.A. Maat-Kievit, C. Sampaio, A. Antonini, F. Stocchi, P. Montagna, V. Toni, M. Guidi, A. Dalla Libera, M. Tinazzi, F. De Pandis, G. Fabbri, S. Goldwurm, A. de Klein, E. Barbosa, L. Lopiano, E. Martignoni, P. Lamberti, N. Vanacore, G. Meco, B.A. Oostralian Parkinson Genetics Network, Early-onset parkinsonism associated with PINK1 mutations: frequency, genotypes, and phenotypes, *Neurology* 65 (2005) 87–95.
- [49] V. Bonifati, P. Rizzu, M.J. van Baren, O. Schaap, G.J. Breedveld, E. Krieger, M.C. Dekker, F. Squitieri, P. Ibanez, M. Joosse, J.W. van Dongen, N. Vanacore, J.C. van Swieten, A. Brice, G. Meco, C.M. van Duijn, B.A. Oostra, P. Heutink, Mutations in the DJ-1 gene associated with autosomal recessive early-onset parkinsonism, *Science* 299 (2002) 256–259.
- [50] C. Marras, A. Lang, B.P. van de Warrenburg, C.M. Sue, S. J. Tabrizi, L. Bertram, S. Mercimek-Mahmutoglu, D. Ebrahimi-Fakhari, T.T. Warner, A. Durr, B. Assmann, K. Lohmann, V. Kostic, C. Klein, Nomenclature of genetic movement disorders: recommendations of the international Parkinson and movement disorder society task force, *Mov. Disord.* 31 (2016) 436–457.
- [51] R. Inzelberg, S. Hassin-Baer, J. Jankovic, Genetic movement disorders in patients of Jewish ancestry, *JAMA Neurol.* 71 (2014) 1567–1572.
- [52] S.W. Scholz, B.S. Jeon, GBA mutations and Parkinson disease: when genotype meets phenotype, *Neurology* 84 (2015) 866–867.
- [53] K. Brockmann, K. Sruiljes, S. Pflederer, A.K. Hauser, C. Schulte, W. Maetzler, T. Gasser, D. Berg, GBA-associated Parkinson's disease: reduced survival and more rapid progression in a prospective longitudinal study, *Mov. Disord.* 30 (2015)

- 407–411.
- [54] E. Sidransky, M.A. Nalls, J.O. Aasly, J. Aharon-Peretz, G. Annesi, E.R. Barbosa, A. Bar-Shira, D. Berg, J. Bras, A. Brice, C.M. Chen, L.N. Clark, C. Condroyer, E.V. De Marco, A. Dürr, M.J. Eblan, S. Fahn, M.J. Farrer, H.C. Fung, Z. Gan-Or, T. Gasser, R. Gershoni-Baruch, N. Giladi, A. Griffith, T. Gurevich, C. Januario, P. Kropp, A.E. Lang, G.J. Lee-Chen, S. Lesag, K. Marder, I.F. Mata, A. Mirelman, J. Mitsui, I. Mizuta, M. Nicoletti, C. Oliveira, R. Ottman, A. Orr-Urtreger, L.V. Pereira, A. Quattrone, E. Rogava, A. Rolfs, H. Rosenbaum, R. Rozenberg, A. Samii, T. Samadpour, C. Schulte, M. Sharma, A. Singleton, M. Spitz, E.K. Tan, N. Tayebi, T. Toda, A.R. Troiano, S. Tsuji, M. Wittstock, T.G. Wolfsberg, Y.R. Wu, C.P. Zabetian, Y. Zhao, S.G. Ziegler, Multicenter analysis of glucocerebrosidase mutations in Parkinson's disease, *N. Engl. J. Med.* 361 (2009) 1651–1661.
- [55] R.N. Alcalay, E. Caccappolo, H. Mejia-Santana, M. Tang, L. Rosado, M. Orbe Reilly, D. Ruiz, B. Ross, M. Verbittsky, S. Kisselev, E. Louis, C. Comella, A. Colcher, D. Jennings, M. Nance, S. Bressman, W.K. Scott, C. Tanner, S. Mickel, H. Andrews, C. Waters, S. Fahn, L. Cote, S. Frucht, B. Ford, M. Rezak, K. Novak, J.H. Friedman, R. Pfeiffer, L. Marsh, B. Hiner, A. Siderowf, H. Payami, E. Molho, S. Factor, R. Ottman, L.N. Clark, K. Marder, Cognitive performance of GBA mutation carriers with early-onset PD: the CORE-PD study, *Neurology* 78 (2012) 1434–1440.
- [56] K. Brockmann, K. Strilijes, A.K. Hauser, C. Schulte, I. Csoti, T. Gasser, D. Berg, GBA-associated PD presents with nonmotor characteristics, *Neurology* 77 (2011) 276–280.
- [57] M.Y. Davis, C.O. Johnson, J.B. Leverenz, D. Weintraub, J.Q. Trojanowski, A. Chen-Plotkin, V.M. Van Deerlin, J.F. Quinn, K.A. Chung, A.L. Peterson-Hiller, L.S. Rosenthal, T.M. Dawson, M.S. Albert, J.G. Goldman, G.T. Stebbins, B. Bernard, Z.K. Wszolek, O.A. Ross, D.W. Dickson, D. Eidelberg, P.J. Mattis, M. Niethammer, D. Yearout, S.C. Hu, B.A. Cholerston, M. Smith, I.F. Mata, T.J. Montine, K.L. Edwards, C.P. Zabetian, Association of GBA mutations and the E326K polymorphism with motor and cognitive progression in Parkinson disease, *JAMA Neurol.* 73 (2016) 1217–1224.
- [58] R. Cilia, S. Tunesi, G. Marotta, E. Cereda, C. Siri, S. Tesi, A.L. Zecchinelli, M. Canesi, C.B. Mariani, N. Meucci, G. Sacilotto, M. Zini, M. Barichella, C. Magnani, S. Duga, R. Asselta, G. Soldà, A. Seresini, M. Seia, G. Pezzoli, S. Goldwurm, Survival and dementia in GBA-associated Parkinson's disease: the mutation matters, *Ann. Neurol.* 80 (2016) 662–673.
- [59] Z. Gan-Or, I. Amshalom, L.L. Kilarski, A. Bar-Shira, M. Gana-Weisz, A. Mirelman, K. Marder, S. Bressman, N. Giladi, A. Orr-Urtreger, Differential effects of severe vs mild GBA mutations on Parkinson disease, *Neurology* 84 (2015) 880–887.
- [60] A. Thaler, T. Gurevich, A. Bar Shira, M. Gana Weisz, E. Ash, T. Shiner, A. Orr-Urtreger, N. Giladi, A. Mirelman, A "dose" effect of mutations in the GBA gene on Parkinson's disease phenotype, *Park. Relat. Disord.* 36 (2017) 47–51.
- [61] M. Seier, A. Hiller, Parkinson's disease and pregnancy: an updated review, *Park. Relat. Disord.* 40 (2017) 11–17.
- [62] G. Benbir, S. Ertan, S. Özekmekci, Successful pregnancy and delivery in a patient with Parkinson's disease under pramipexole treatment, *Presse Med.* 43 (2014) 83–85.
- [63] T. Serikawa, T. Shimohata, M. Akashi, A. Yokoseki, M. Tsuchiya, A. Hasegawa, K. Haino, R. Koike, K. Takakuwa, K. Tanaka, K. Tanaka, M. Nishizawa, Successful twin pregnancy in a patient with parkin-associated autosomal recessive juvenile parkinsonism, *BMC Neurol.* 11 (2011) 72.
- [64] D. Lamichhane, N.S. Narayanan, P. Gonzalez-Alegre, Two cases of pregnancy in Parkinson's disease, *Park. Relat. Disord.* 20 (2014) 239–240.
- [65] F. Jacquemard, J.C. Palaric, H. Allain, J.R. Giraud, Parkinson disease and pregnancy. A propos of a case, *J. Gynecol. Obstet. Biol. Reprod. Paris.* 19 (1990) 461–463.
- [66] T. Routiot, S. Lurel, E. Denis, P. Barbarino-Monnier, Parkinson's disease and pregnancy: case report and literature review, *J. Gynecol. Obstet. Biol. Reprod.* 29 (2000) 454–457.
- [67] B.J. Robottom, R.J. Mullins, L.M. Shulman, Pregnancy in Parkinson's disease: case report and discussion, *Expert Rev. Neurother.* 8 (2008) 1799–1805.
- [68] M. Mucchiut, E. Belgrado, D. Cutuli, A. Antonini, P. Bergonzi, Pramipexole treated Parkinson's disease during pregnancy, *Mov. Disord.* 19 (2004) 1114–1115.
- [69] L.M. Shulman, A. Minagar, W.J. Weiner, The effect of pregnancy in Parkinson's disease, *Mov. Disord.* 15 (2000) 132–135.
- [70] M. Scott, M. Chowdhury, Pregnancy in Parkinson's disease: unique case report and review of the literature, *Mov. Disord.* 20 (2005) 1078–1079.
- [71] L.I. Golbe, Parkinson's disease and pregnancy, *Neurology* 37 (1987) 1245–1249.
- [72] S.M. Krnack, E.M. Mowry, A. Colcher, S. Horn, L.I. Golbe, Movement disorders and pregnancy: a review of the literature, *Mov. Disord.* 25 (2010) 665–671.
- [73] Z. Tüfekçioğlu, H. Hanağası, G. Yalçın Çakmaklı, B. Elibol, F.E. Tokuçoğlu, Z.E. Kaya, S. Ertan, S. Özekmekçi, M. Emre, Use of anti-Parkinson medication during pregnancy: a case series, *J. Neurol.* 265 (2018) 1922–1929.
- [74] B. Asha, N. Hansali, P. Apoorva, Successful birth of an IVF baby in a patient with Parkinson's disease, *J. Hum. Reprod. Sci.* 3 (2010) 42–43.
- [75] S.M. Rubin, Parkinson's disease in women, *Disease-a-Month* 53 (2007) 206–213.
- [76] S. Nageshwaran, M. Smith, Y.M. Bordelon, Movement disorders and pregnancy, in: A. Klein, M.A. O'Neal, C. Scifres, J. Waters, J.H. Waters (Eds.), *Neurological Illness in Pregnancy: Principles and Practice*, first ed., Wiley-Blackwell, Hoboken, 2016, pp. 179–190.
- [77] N.M. Gatto, D. Deapen, S. Stoyanoff, R. Pinder, S. Narayan, Y. Bordelon, B. Ritz, Lifetime exposure to estrogens and Parkinson's disease in California teachers, *Park. Relat. Disord.* 20 (2014) 1149–1156.
- [78] K.A. Disshon, J.W. Boja, D.E. Dluzen, Inhibition of striatal dopamine transporter activity by 17 β -estradiol, *Eur. J. Pharmacol.* 345 (1998) 207–211.
- [79] M.D. Benedetti, D.M. Maraganore, J.H. Bower, S.K. McDonnell, B.J. Peterson, J.E. Ahlsgog, D.J. Schaid, W.A. Rocca, Hysterectomy, menopause, and estrogen use preceding Parkinson's disease: an exploratory case-control study, *Mov. Disord.* 16 (2001) 830–837.
- [80] K.E. Lyons, J.P. Hubble, A.I. TrCoster, R. Pahwa, W.C. Koller, Gender differences in Parkinson's disease, *Clin. Neuropharmacol.* 21 (1998) 118–121.
- [81] M. Nitkowska, M. Czyzyk, A. Friedman, Reproductive life characteristics in females affected with Parkinson's disease and in healthy control subjects - a comparative study on Polish population, *Neurol. Neurochir. Pol.* 48 (2014) 322–327.
- [82] P. Ragonese, M. D'Amelio, G. Salemi, P. Aridon, M. Gammino, A. Epifanio, L. Morgante, G. Savettieri, Risk of Parkinson disease in women: effect of reproductive characteristics, *Neurology* 62 (2004) 2010–2014.
- [83] R. Yadav, G. Shukla, V. Goyal, S. Singh, M. Behari, A case control study of women with Parkinson's disease and their fertility characteristics, *J. Neurol. Sci.* 319 (2012) 135–138.
- [84] M. Picillo, A. Nicoletti, V. Fetoni, B. Garavaglia, P. Barone, M.T. Pellecchia, The relevance of gender in Parkinson's disease: a review, *J. Neurol.* 264 (2017) 1583–1607.
- [85] R. Liu, D. Baird, Y. Park, N.D. Freedman, X. Huang, A. Hollenbeck, A. Blair, H. Chen, Female reproductive factors, menopausal hormone use, and Parkinson's disease, *Mov. Disord.* 29 (2014) 889–896.
- [86] L.M. Shulman, Is there a connection between estrogen and Parkinson's disease? *Park. Relat. Disord.* 8 (2002) 289–295.
- [87] P. Wang, J. Li, S. Qiu, H. Wen, J. Du, Hormone replacement therapy and Parkinson's disease risk in women: a meta-analysis of 14 observational studies, *Neuropsychiatric Dis. Treat.* 11 (2015) 59–66.
- [88] R. Popat, S. Van Den Eeden, C. Tanner, V. McGuire, A. Bernstein, D. Bloch, A. Leimpeter, L. Nelson, Effect of reproductive factors and postmenopausal hormone use on the risk of Parkinson, *Neurology* 65 (2005) 383–390.
- [89] J.I. Lundin, T.G. Ton, A.Z. LaCroix, W.T. Longstreth, G.M. Franklin, P.D. Swanson, T. Smith-Weller, B.A. Racette, H. Checkoway, Formulations of hormone therapy and risk of Parkinson's disease, *Mov. Disord.* 29 (2014) 1631–1636.
- [90] P.C. Thulin, W. Woodward, J.H. Carter, J. Nutt, Levodopa in human breast milk. Clinical implications, *Neurology* 50 (1998) 1920–1921.
- [91] D. Tolson, V. Fleming, E. Scharta, Coping with menstruation: understanding the needs of women with Parkinson's disease, *J. Adv. Nurs.* 40 (2002) 513–521.
- [92] G.G. Briggs, R.K. Freeman, S.J. Yaffe, *Drugs in Pregnancy and Lactation*, fourth ed., Williams and Wilkins Baltimore, 1994.
- [93] Y. Zlotnik, N. Giladi, A. Hilel, Y. Shapira, S. Goldstein, T. Gurevich, Levodopa intestinal gel (LCIG) infusion during pregnancy and delivery: first documented case, *Park. Relat. Disord.* 20 (2014) 1317–1318.
- [94] E.S. Canales, I.C. Garcia, J.E. Ruiz, A. Zarate, Bromocriptine as prophylactic therapy in prolactinoma during pregnancy, *Fertil. Steril.* 36 (1981) 524–526.
- [95] K. K. Martikainen, T.H. Luukkaala, R.J. Marttila, Parkinson's disease and working capacity, *Mov. Disord.* 21 (2006) 2187–2191.
- [96] B. Jasinska-Myga, M.G. Heckman, C. Wider, J.D. Putzke, Z.K. Wszolek, R. J. Uitti, Loss of ability to work and ability to live independently in Parkinson's disease, *Park. Relat. Disord.* 18 (2012) 130–135.
- [97] P. Banks, M. Lawrence, The Disability Discrimination Act, a necessary, but not sufficient safeguard for people with progressive conditions in the workplace? The experiences of younger people with Parkinson's disease, *Disabil. Rehabil.* 28 (2006) 13–24.
- [98] S. Subramanian, A.F. Holtyn, B.P. Jarvis, M.N. Koffarnus, J.S. Leoutsakos, K. Silverman, Illicit drug use and work in a model therapeutic workplace, *Drug Alcohol Depend.* 191 (2018) 110–116.
- [99] P. Jennum, M. Zoetmulder, L. Korbo, J. Kjellberg, The health related, social, and economic consequences of Parkinson's disease: a controlled national study, *J. Neurol.* 258 (2011) 1497–1506.
- [100] R.D. Conger, M.A. Rueter, G.H. Elder Jr., Couple resilience to economic pressure, *J. Personal. Soc. Psychol.* 76 (1999) 54–71.
- [101] M. Nordstrom, I. Lubkin, Quality of life, in: I.M. Lubkin (Ed.), *Chronic Illness: Impact and Interventions*, Jones & Bartlett, Boston, 1990, pp. 136.
- [102] S. M. Calne, S.C. Lidstone, A. Kumar, Psychosocial issues in young-onset Parkinson's disease: current research and challenges, *Park. Relat. Disord.* 142 (2008) 143–150.
- [103] K.B. Bhattacharya, M. Rosa-Grilo, Sexual dysfunctions in Parkinson's disease: an underrated problem in a much discussed disorder, *Int. Rev. Neurobiol.* 134 (2017) 859–876.
- [104] K. Maier, S.M. Calne, Informal caregiving: a valuable part of the health care team, in: M. Ebad, R.F. Pfeiffer (Eds.), *Parkinson's Disease*, CRC Press, Florida, 2005, pp. 999–1008.
- [105] P.E. Mosley, R. Moodie, N. Dissanayaka, Caregiver burden in Parkinson disease: a critical review of recent literature, *J. Geriatr. Psychiatry Neurol.* 30 (2017) 235–252.
- [106] M.A. Thenganatt, J. Jankovic, Psychogenic (functional) parkinsonism, in: M. Hallett, J. Stone, A. Carson (Eds.), *Functional Neurologic Disorders*, Handbook of Clinical Neurology, Elsevier, Amsterdam, Netherlands, 2017, pp. 259–262.
- [107] M.M. Wickremaratchi, M.D. Knipe, B.S. Sastry, E. Morgan, A. Jones, R. Salmon, R. Weiser, M. Moran, D. Davies, L. Ebenezer, S. Raha, N.P. Robertson, C.C. Butler, Y. Ben-Shlomo, H.R. Morris, The motor phenotype of Parkinson's disease in relation to age at onset, *Mov. Disord.* 26 (2011) 457–463.
- [108] A. Friedman, Old-onset Parkinson's disease compared with young-onset disease: clinical differences and similarities, *Acta Neurol. Scand.* 89 (1994) 258–261.
- [109] M.A. Hely, J.G. Morris, W.G. Reid, D.J. O'Sullivan, P.M. Williamson, G.A. Broe, M.A. Adena, Age at onset: the major determinant of outcome in Parkinson's disease, *Acta Neurol. Scand.* 92 (1995) 455–463.
- [110] P. Giovannini, I. Piccolo, S. Genitri, P. Soliveri, F. Girotti, G. Geminiani, G. Scigliano, T. Caraceni, Early-onset Parkinson's disease, *Mov. Disord.* 6 (1991)

- 36–42.
- [111] H. Nagayama, M. Hamamoto, C. Nito, S. Takagi, T. Miyazaki, Y. Katayama, Initial symptoms of Parkinson's disease with elderly onset, *Gerontology* 46 (2000) 129–132.
- [112] G. Pagano, N. Ferrara N, D.J. Brooks, N. Pavese, Age at onset and Parkinson disease phenotype, *Neurology* 86 (2016) 1400–1407.
- [113] J. Jankovic, A.S. Kapadia, Functional decline in Parkinson's disease, *Arch. Neurol.* 58 (2001) 1611–1615.
- [114] S.M. van Rooden, W.J. Heiser, J.N. Kok, D. Verbaan, J. J van Hilten, J. Marinus, The identification of Parkinson's disease subtypes using cluster analysis: a systematic review, *Mov. Disord.* 25 (2010) 96–978.
- [115] S.M. Fereshtehnejad, S.R. Romanets, J.B. Anang, V. Latreille, J.F. Gagnon, R.B. Postuma, New clinical subtypes of Parkinson disease and their longitudinal progression: a prospective cohort comparison with other phenotypes, *JAMA Neurol.* 72 (2015) 863–873.
- [116] R. S Eisinger, C. W Hess, D. Martinez-Ramirez, L. Almeida, K. D Foote, M.S. Okun, A. Gunduz, Motor subtype changes in early Parkinson's disease, *Park. Relat. Disord.* 43 (2017) 67–72.
- [117] S.Y. Liu, J.J. Wu, J. Zhao, S.F. Huang, Y.X. Wang, J.J. Ge, P. Wu, C.T. Zuo, Z.T. Ding, J. Wang, Onset-related subtypes of Parkinson's disease differ in the patterns of striatal dopaminergic dysfunction: a positron emission tomography study, *Park. Relat. Disord.* 21 (2015) 1448–1453.
- [118] M. DeLong, T. Wichmann, Update on models of basal ganglia function and dysfunction, *Park. Relat. Disord.* 15 (Suppl. 3) (2009) S237–S240.
- [119] K.L. Poston, D. Eidelberg, Functional brain networks and abnormal connectivity in the movement disorders, *Neuroimage* 62 (2012) 2261–2270.
- [120] M. Carbon, Y. Ma, A. Barnes, V. Dhawan, T. Chaly, M.F. Ghilardi, D. Eidelberg, Caudate nucleus: influence of dopaminergic input on sequence learning and brain activation in Parkinsonism, *Neuroimage* 21 (2004) 1497–1507.
- [121] V. Sossi, R. de la Fuente-Fernandez, M. Schulzer, J. Adams, A.J. Stoessl, Age related differences in levodopa dynamics in Parkinson's: implications for motor complications, *Brain* 129 (2006) 1050–1058.
- [122] R. de la Fuente-Fernández, M. Schulzer, L. Kuramoto, J. Cragg, N. Ramachandiran, W.L. Au, E. Mak, J. McKenzie, S. McCormick, V. Sossi, T.J. Ruth, C.S. Lee, D.B. Calne, A.J. Stoessl, Age-specific progression of nigrostriatal dysfunction in Parkinson's disease, *Ann. Neurol.* 69 (2011) 803–810.
- [123] G. Alves, T. Wentzel-Larsen, D. Aarsland, J.P. Larsen, Progression of motor impairment and disability in Parkinson disease: a population-based study, *Neurology* 65 (2005) 1436–1441.
- [124] R. Inzelberg, E. Schecthman, D. Paleacu, L. Zach, R. Bonwitt, R.L. Carasso, P. Nisipeanu, Onset and progression of disease in familial and sporadic Parkinson's disease, *Am. J. Med. Genet.* 124 (2004) 255–258.
- [125] V. Spica, T. Pekmezovic, M. Svetel, V.S. Kostic, Prevalence of non-motor symptoms in young-onset versus late-onset Parkinson's disease, *J. Neurol.* 260 (2013) 131–137.
- [126] R. Cilia E. Cereda, C. Klersy, M. Canesi, A.L. Zecchinelli, C.B. Mariani, S. Tesesi, G. Sacilotto, N. Meucci, M. Zini, C. Ruffmann, I.U. Isaias, S. Goldwurm, G. Pezzoli, Parkinson's disease beyond 20 years, *J. Neurol. Neurosurg. Psychiatry* 86 (2015) 849–855.
- [127] C. Warren Olanow, K. Kieburtz, O. Rascol, Stalevo reduction in dyskinesia evaluation in Parkinson's disease (STRIDE-PD) investigators, factors predictive of the development of levodopa-induced dyskinesia and wearing-off in Parkinson's disease, *Mov. Disord.* 28 (2013) 1064–1071.
- [128] V. Kostic, S. Przedborski, E. Flaster, N. Sternic, Early development of levodopa-induced dyskinesias and response fluctuations in young-onset Parkinson's disease, *Neurology* 41 (1991) 202–205.
- [129] A. Pantelatos, F. Fornadi, Clinical features and medical treatment of Parkinson's disease in patient groups selected in accordance with age at onset, *Adv. Neurol.* 60 (1993) 690–697.
- [130] N. Kumar, J.A. Van Gerpen, J.H. Bower, J.E. Ahlskog, Levodopa-dyskinesia incidence by age of Parkinson's disease onset, *Mov. Disord.* 20 (2005) 342–344.
- [131] J.A. Van Gerpen, N. Kumar, J.H. Bower, S. Weigand, J.E. Ahlskog, Levodopa-associated dyskinesia risk among Parkinson disease patients in Olmsted County, Minnesota, 1976–1990, *Arch. Neurol.* 63 (2006) 205–209.
- [132] J. E Ahlskog, Beating a dead horse: dopamine and Parkinson disease, *Neurology* 69 (2007) 1701–1711.
- [133] S.H. Fox, A. E Lang, Don't delay, start today, *Brain* 137 (2014) 2628–2630.
- [134] R. Cilia, A. Akpalu, F.S. Sarfo, M. Cham, M. Amboni, E. Cereda, M. Fabbri, P. Adjei, J. Akassi, A. Bonetti, G. Pezzoli, The modern pre-levodopa era of Parkinson's disease: insights into motor complications from sub-Saharan Africa, *Brain* 137 (2014) 2731–2742.
- [135] A.J. Espay, A.E. Lang, Common myths in the use of levodopa in Parkinson disease: when clinical trials misinform clinical practice, *JAMA Neurol.* 74 (2017) 633–634.
- [136] S.Y. Lim, W. Poewe, A.H. Tan, Levodopa and Parkinson disease-myths revisited, *JAMA Neurol.* 74 (2017) 1270.
- [137] V. Kostic, Treatment of young-onset Parkinson's disease: role of dopamine receptor agonists, *Park. Relat. Disord.* 15 (2010) S71–S75.
- [138] J. Jankovic, Parkinson's disease therapy: tailoring choices for early and late disease, young and old patients, *Clin. Neuropharmacol.* 23 (2000) 252–261.
- [139] O. Rascol, D.J. Brooks, A.D. Korczyn, P.P. De Deyn, C. E Clarke, A.E. Lang, A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa, *N. Engl. J. Med.* 42 (2000) 1484–1491.
- [140] A.J. Espay, A. E Lang, Levodopa and Parkinson disease-myths revisited-reply, *JAMA Neurol.* 74 (2017) 1270–1271.
- [141] R. Mehanna, W.G. Ondo, Sleep problems in Parkinson's disease patients, *Neurodegener. Dis. Manag.* 1 (2011) 307–321.
- [142] L. Vela, J.C. Martínez Castrillo, P. García Ruiz P, C. Gasca-Salas, Y. Macías Macías, E. Pérez Fernández, I. Ybot, E. Lopez Valdés, M.M. Kurtis, L.J. Posada Rodriguez, M. Mata, C. Ruiz Huete, M. Eimil, C. Borrué, J. Del Val, L. López-Manzanares, A. Rojo Sebastian, R. Marasescu, The high prevalence of impulse control behaviors in patients with early-onset Parkinson disease: a cross-sectional multicenter study, *J. Neurol. Sci.* 368 (2016) 150–154.
- [143] J.C. Corvol, F. Artaud, F. Cormier-Dequaire, O. Rascol, F. Durif, P. Derkinderen, A.R. Marques, F. Bourdain, J.P. Brandel, F. Pico, L. Lacomblez, C. Bonnet, C. Brefel-Courbon, F. Ory-Magne, D. Grabli, S. Klebe, G. Mangone, H. You, V. Mesnage, P.C. Lee, A. Brice, M. Vidailhet, A. ElbazDIGPD Study Group, Longitudinal analysis of impulse control disorders in Parkinson disease, *Neurology* 91 (2018) e189–e201.
- [144] R. Biundo, L. Weis, G. Abbruzzese, G. Calandra-Buonaura, P. Cortelli, M.C. Jori, L. Lopiano, R. Marconi, A. Matinella, F. Morgante, A. Nicoletti, T. Tamburini, M. Tinazzi, M. Zappia, R.J. Vorovenci, A. Antonini, Impulse control disorders in advanced Parkinson's disease with dyskinesia: the ALTHEA study, *Mov. Disord.* 32 (2017) 1557–1565.
- [145] A. Tarakad, J. Jankovic, Diagnosis and management of Parkinson's disease, *Semin. Neurol.* 37 (2017) 118–126.
- [146] W.H. Poewe, G. Deuschl, A. Gordin, E.R. Kultalahti, M. Leinonen-Celomen Study Group, Efficacy and safety of entacapone in Parkinson's disease patients with suboptimal levodopa response: a 6-month randomized placebo-controlled double-blind study in Germany and Austria (Celomen study), *Acta Neurol. Scand.* 105 (2002) 245–255.
- [147] Parkinson study group, A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study, *Arch. Neurol.* 62 (2005) 241–248.
- [148] L.V. Metman, P. Del Dotto, K. LePoole, S. Konitsiotis, J. Fang, T.N. Chase, Amantadine for levodopa induced dyskinesias: a 1-year follow-up study, *Arch. Neurol.* 56 (1999) 1383–1386.
- [149] F. Ory-Magne, J.C. Corvol, J.P. AzulayNS-Park CIC Network, Withdrawing amantadine in dyskinetic patients with Parkinson disease: the AMANDYSK trial, *Neurology* 82 (2014) 300–307.
- [150] H.L. Tyne, J. Parsons, A. Sinnott, S.H. Fox, N.A. Fletcher, M.J. Steiger, A 10 year retrospective audit of long-term apomorphine use in Parkinson's disease, *J. Neurol.* 251 (2004) 1370–1374.
- [151] P. Krack, P. Pollak, P. Limousin, D. Hoffmann, J. Xie, A. Benazzouz, A.L. Benabid, Subthalamic nucleus or internal pallidal stimulation in young onset Parkinson's disease, *Brain* 121 (1998) 451–457.
- [152] K. Wirdefeldt, P. Odin, D. Nyholm, Levodopa-carbidopa intestinal gel in patients with Parkinson's disease: a systematic review, *CNS Drugs* 30 (2016) 381–404.
- [153] R. Pahwa, C.M. Tanner, R.A. Hauser, S.H. Isaacson, P.A. Nausieda, D. D Truong, P. Agarwal, K.L. Hull, K. E Lyons, R. Johnson, M.J. Stempien, ADS-5102 (amantadine) extended-release capsules for levodopa-induced dyskinesia in Parkinson disease (EASE LID study): a randomized clinical trial, *JAMA Neurol.* 74 (2017) 941–949.
- [154] S.T. Tsai, H.Y. Hung, T.C. Hsieh, S.H. Lin, S.Z. Lin, S.Y. Chen, Long-term outcome of young onset Parkinson's disease after subthalamic stimulation—a cross-sectional study, *Clin. Neurol. Neurosurg.* 115 (2013) 2082–2087.
- [155] R. Katzenschlager, W. Poewe, O. Rascol, C. Trenkwalder, G. Deuschl, K.R. Chaudhuri, T. Henriksen, T. van Laar, K. Spivey, S. Vel, H. Staines, A. Lees, Apomorphine subcutaneous infusion in patients with Parkinson's disease with persistent motor fluctuations (TOLEDO): a multicentre, double-blind, randomised, placebo-controlled trial, *Lancet Neurol.* 17 (2018) 749–759.
- [156] D. Vijayakumar, J. Jankovic, Drug-induced dyskinesia, Part 1: treatment of levodopa-induced dyskinesia, *Drugs* 76 (2016) 759–777.
- [157] K.A. Grosset, I. Bone, D.G. Grosset, Suboptimal medication adherence in Parkinson's disease, *Mov. Disord.* 20 (2005) 1502–1507.
- [158] Y.J. Wei, F.B. Palumbo, L. Simoni-Wastila, L.M. Shulman, B. Stuart, R. Beardsley, C.H. Brown, Antiparkinson drug adherence and its association with health care utilization and economic outcomes in a Medicare Part D population, *Value Health* 17 (2014) 196–204.
- [159] A. Schrag, D. Morley, N. Quinn, M. Jahanshahi, Impact of Parkinson's disease on patients' adolescent and adult children, *Park. Relat. Disord.* 10 (2004) 391–397.
- [160] J.H. Carter, B.J. Stewart, P.G. Archbold, I. Inoue, J. Jaglin, M. Lannon, E. Rost-Ruffner, M. Tennis, M.P. McDermott, D. Amyot, R. Barter, L. Cornelius, C. Demong, J. Dobson, J. Duff, J. Erickson, N. Gardiner, L. Gauger, P. Gray, B. Kanigan, B. Kiryluk, P. Lewis, K. Mistura, T. Malapira, K. Zoog, Living with a person who has Parkinson's disease: the spouse's perspective by stage of disease, Parkinson's Study Group, *Mov. Disord.* 13 (1998) 20–28.
- [161] M. Ravenek, D.L. Rudman, M.E. Jenkins, S. Spaulding, Understanding uncertainty in young-onset Parkinson disease, *Chronic Illness* 13 (2017) 288–298.
- [162] S. Chaudhary, D. Joshi, A. Pathak, V.N. Mishra, R.N. Chaurasia, G. Gupta, Comparison of cognitive profile in young- and late-onset Parkinson's disease patients, *Ann. Indian Acad. Neurol.* 21 (2018) 130–132.
- [163] K.S. Kostic, S.R. Filipovic, D. Lecic, D. Momcilovi, D. Sokic, N. Sternic, Effect of age at onset on frequency of depression in Parkinson's disease, *J. Neurol. Neurosurg. Psychiatry* 57 (1994) 1265–1267.
- [164] N.N. Dissanayaka, A. Sellbach, S. Matheson, J.D. O'Sullivan, P.A. Silburn, G.J. Byrne, R. Marsh, G.D. Mellick, Anxiety disorders in Parkinson's disease: prevalence and risk factors, *Mov. Disord.* 25 (2010) 838–845.
- [165] X. Guo, W. Song, K. Chen, X. Chen, Z. Zheng, B. Cao, R. Huang, B. Zhao, Y. Wu, H.F. Shang, Gender and onset age-related features of non-motor symptoms of patients with Parkinson's disease—a study from Southwest China, *Park. Relat. Disord.* 19 (2013) 961–965.

- [168] V. Voon, K. Hassan, M. Zurowski, S. Duff-Canning, M. de Souza, S. Fox, A.E. Lang, J. Miyasaki, Prospective prevalence of pathologic gambling and medication association in Parkinson disease, *Neurology* 66 (2006) 1750–1752.
- [169] D. Weintraub, J. Koester, M.N. Potenza, A.D. Siderowf, M. Stacy, V. Voon, J. Whetteckey, G.R. Wunderlich, A.E. Lang, Impulse control disorders in Parkinson disease: a cross-sectional study of 3090 patients, *Arch. Neurol.* 67 (2010) 589–595.
- [170] P. Barbosa, A. Djamshidian, A.J. Lees, T.T. Warner, The outcome of dopamine dysregulation syndrome in Parkinson's disease: a retrospective postmortem study, *Mov Disord Clin Pract* 5 (2018) 519–522.
- [171] A.W. Willis, M. Schootman, N. Kung, B.A. Racette, Epidemiology and neuropsychiatric manifestations of young onset Parkinson's disease in the United States, *Park. Relat. Disord.* 19 (2013) 202–206.
- [172] R.J. Stolwyk, K.A. Scally, J.L. Charlton, J.L. Bradshaw, R. Iansek, N. Georgiou-Karistianis, Self-regulation of driving behavior in people with Parkinson disease, *Cogn. Behav. Neurol.* 28 (2015) 80–91.
- [173] I. Robledo, J. Jankovic, Media hype, Patient and scientific perspectives on misleading medical news, *Mov. Disord.* 32 (2017) 1319–1323.
- [174] M. van der Eijk, F.A. Nijhuis, M.J. Faber, B.R. Bloem, Moving from physician-centered care towards patient-centered care for Parkinson's disease patients, *Park. Relat. Disord.* 19 (2013) 923–927.
- [175] R. Bouça-Machado, H. Lennaerts-Kats, B. Bloem, J.J. Ferreira, Why palliative care applies to Parkinson's disease, *Mov. Disord.* 33 (2018) 750–753.
- [176] J.M. Miyasaki, B. Kluger, Palliative care for Parkinson's disease: has the time come? *Curr. Neurol. Neurosci. Rep.* 15 (2015) 26.
- [177] S.-M. Fereshtehnejad, Strategies to maintain quality of life among people with Parkinson's disease: what works? *Neurodegener. Dis. Manag.* 6 (2016) 399–415.
- [178] I.H. Sturkenboom, M.J. Graff, J.C. Hendriks, Y. Veenhuizen, M. Munneke, B.R. Bloem, M.W. Nijhuis-van der Sanden, OTIP study group, Efficacy of occupational therapy for patients with Parkinson's disease: a randomised controlled trial, *Lancet Neurol.* 13 (2014) 557–566.
- [179] W.G. Reid, M.A. Hely, J.G. Morris, C. Loy, G.M. Halliday, Dementia in Parkinson's disease: a 20-year neuropsychological study (sydney multicentre study), *J. Neurol. Neurosurg. Psychiatry* 82 (2011) 1033–1037.
- [180] W.R. Gibb, A.J. Lees, A comparison of clinical and pathological features of young- and old-onset Parkinson's disease, *Neurology* 38 (1988) 1402–1406.
- [181] A. Kummer, F. Cardoso, A.L. Teixeira, Frequency of psychiatric disorders in young-onset Parkinson's disease does not differ from typical-onset Parkinson's disease, *Park. Relat. Disord.* 15 (2009) 153–155.
- [182] L.M. Shulman, R.L. Taback, J. Bean, W.J. Weiner, Comorbidity of the nonmotor symptoms of Parkinson's disease, *Mov. Disord.* 16 (2001) 507–510.
- [183] D. Latella, M.G. Maggio, G. Maresca, A.F. Saporoso, M. Le Cause, A. Manuli, D. Milardi, P. Bramanti, R. De Luca, R.S. Calabrò, Impulse control disorders in Parkinson's disease: a systematic review on risk factors and pathophysiology, *J. Neurol. Sci.* 398 (2019) 101–106.
- [184] P. Barone, A. Antonini, C. ColosimoPriamo Study Group, The PRIAMO study: a multicenter assessment of nonmotor symptoms and their impact on quality of life in Parkinson's disease, *Mov. Disord.* 24 (2009) 1641–1649.
- [185] P. Martinez-Martin, C. Rodriguez-Blazquez, K. Abe, K.B. Bhattacharyya, B.R. Bloem, F.J. Carod-Artal, R. Prakash, R.A. Esselink, C. Falup-Pecurariu, M. Gallardo, P. Mir, Y. Naidu, A. Nicoletti, K. Sethi, Y. Tsuboi, J.J. van Hilten, M. Visser, M. Zappia, K.R. Chaudhuri, International study on the psychometric attributes of the non-motor symptoms scale in Parkinson's disease, *Neurology* 73 (2009) 1584–1591.
- [186] P. Martinez-Martin, C. Falup Pecurariu, P. Odin, J.J. van Hilten, A. Antonini, J.M. Rojo-Abuin, V. Borges, C. Trenkwalder, D. Aarsland, D.J. Brooks, K. Ray Chaudhuri, Gender-related differences in the burden of non-motor symptoms in Parkinson's disease, *J. Neurol.* 25 (2012) 1639–1647.
- [187] M.Z. Zhou, J. Gan, Y.R. Wei, X.Y. Ren, W. Chen, Z.G. Liu, The association between non-motor symptoms in Parkinson's disease and age at onset, *Clin. Neurol. Neurosurg.* 115 (2013) 2103–2107.
- [188] R. Mahale, R. Yadav, P.K. Pal, Quality of sleep in young onset Parkinson's disease: any difference from older onset Parkinson's disease, *Park. Relat. Disord.* 21 (2015) 461–464.